I think we are probably at bottom too... just basic reason says that if they just raised $110 million at $4.5 through a smart investor pool in only 3 days.....there is demand and it's oversold. Bottom should have been roughly 4.5.
Add in the recent HAE news and we should see an upswing past 4.5 maybe approaching $5.
@Agri- thanks for posting the SNRE article, I am not saying to hype like SNRE. I am saying move faster.
I guess maybe it's harder to covert an existing study than laymen like me expect (different technical experts for different indications leading the studies). They probably must be also having difficulty with the hospitals in Brazil. I think the study involves periodic viral load measurements and it could be tough to get that equipment available and people trained to use it. Maybe in the end the delays will be justified. If they have a well run study that crosses all the T's and the results are clear, it's probably in our best interest overall rather than a messy study where the results are questioned. Probably was super important to have everything in place first and then enroll patients because we know the sooner the treatment starts, the better the results. Same thing with Acyclovir for cold sores and any other anti-viral, including remdesivir.
So I guess I am cheering up when I think longer about the galid trial... sorry my friends!
Good chance we get something positive from the animal study first. Hopefully the new HAE PR changes the momentum.
Market Data 
Markets 
AI
